Search For

From platforms to pathways: imaging innovation, quantitative biomarkers, and clinical translation in hepatocellular carcinoma

When a hazard ratio is not enough: non-proportional hazards are reshaping the interpretation of phase III trials in hepatocellular carcinoma

Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma

Malnutrition in MASLD-related hepatocellular carcinoma: assessment limitations, multidimensional mechanisms, and microbiome-based interventions

Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma

Gut microbiota as predictors of immunotherapy response in hepatocellular carcinoma

Hepatocellular carcinoma tumor immune microenvironment: heterogeneity and therapeutic strategies

A systematic review of comparative economic analyses of systemic therapies for hepatocellular carcinoma

Targeting gut microbiota to overcome immunotherapy resistance in hepatocellular carcinoma: from mechanisms to clinical practice

An activated CD8⁺ T cell-based signature stratifies prognosis and suggests differential sensitivity to immune checkpoint inhibitors in hepatocellular carcinoma

Impact of metabolic reprogramming on the immune response in hepatocellular carcinoma

Yttrium-90 combination therapies in hepatocellular carcinoma: current evidence and future directions